High frequency of HLA-B44 allelic losses in human solid tumors.
暂无分享,去创建一个
F. Garrido | M. López-Nevot | T. Cabrera | A. Collado | I. Maleno | M. Redondo | María Angustias Parejo Fernández
[1] D. Geraghty,et al. Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.
[2] F. Garrido,et al. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 , 2002, Cancer Immunology, Immunotherapy.
[3] D. Jäger,et al. Clinical cancer vaccine trials. , 2002, Current opinion in immunology.
[4] C. Lutz,et al. Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules , 2002, Immunogenetics.
[5] H. Schreiber,et al. Immunodominance and tumor escape. , 2002, Seminars in cancer biology.
[6] U. Ritz,et al. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. , 2001, International journal of oncology.
[7] J. Shabanowitz,et al. Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors1 , 2001, The Journal of Immunology.
[8] M. Ikeda,et al. High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. , 2001, Biochemical and biophysical research communications.
[9] P. Stern,et al. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells , 2000, Immunogenetics.
[10] F. Garrido,et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.
[11] F. Garrido,et al. Criteria to define HLA haplotype loss in human solid tumors. , 2000, Tissue antigens.
[12] J. McCluskey,et al. Distinct Functions of Tapasin Revealed by Polymorphism in MHC Class I Peptide Loading1 , 2000, The Journal of Immunology.
[13] F. Foury,et al. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. , 1999, Cancer research.
[14] C. Figdor,et al. A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia , 1999, The Journal of experimental medicine.
[15] A. Sewell,et al. HLA‐A*0201 presents TAP‐dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin , 1998, European journal of immunology.
[16] B. Seliger,et al. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. , 1998, Cancer research.
[17] A. Nouri,et al. Relevance of the immune system in human urological malignancies: prospective for future clinical treatments. , 1998, Urology.
[18] P. Cresswell,et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. , 1998, Immunity.
[19] C. Meijer,et al. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression , 1998, The Lancet.
[20] L. Old,et al. Cancer Tumor antigens. , 1997, Current opinion in immunology.
[21] R. Tampé,et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. , 1997, Science.
[22] F. Oesch,et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.
[23] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[24] P. van Endert,et al. Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.
[25] F. Garrido,et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.
[26] F. Garrido,et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. , 1996, Human immunology.
[27] F. Marincola,et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.
[28] P. Stern,et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer , 1995, Nature Medicine.
[29] X. Sastre,et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.
[30] A. Harris,et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.
[31] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[32] J. Bodmer,et al. Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms , 1993, Annals of the New York Academy of Sciences.
[33] F. Esteban,et al. Presence of hpv 16 sequences in laryngeal carcinomas , 1990, International journal of cancer.
[34] R. Versteeg,et al. c‐myc down‐regulates class I HLA expression in human melanomas. , 1988, The EMBO journal.
[35] A. McMichael,et al. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.
[36] J. Hors,et al. HLA and cancer. , 1984, Transplantation proceedings.
[37] P. Romero,et al. A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 , 2005, Immunogenetics.
[38] S. Rodríguez de Córdoba,et al. HLA antigens in a sample of the Spanish population: Common features among Spaniards, Basques, and Sardinians , 2004, Human Genetics.
[39] F. Garrido,et al. Analysis of HLA expression in human tumor tissues , 2002, Cancer Immunology, Immunotherapy.
[40] F. Garrido,et al. MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.
[41] F. Garrido,et al. Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.
[42] H. Inoko,et al. New polymorphic microsatellite markers in the human MHC class I region. , 1999, Tissue antigens.
[43] Ian Tomlinson,et al. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog , 1999, Nature medicine.
[44] R. Rees,et al. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. , 1997, British Journal of Cancer.
[45] Dominique Charron,et al. HLA : genetic diversity of HLA functional and medical implication , 1997 .
[46] A. Hill,et al. MHC loss in colorectal tumours: evidence for immunoselection? , 1992, Cancer surveys.